ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

LAWRENCE SALAMONE MD

PONCE DE LEON #735 SUITE 211 TORRE DE AUXILIO MUTUO

San juan | Puerto Rico | 00917

(787) 753-6170

Incorrect Info?
Search this name in Dollars for Docs »
See this provider's services »

At A Glance: This Prescriber in 2012

Nephrology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,380Medicare Part D Prescriptions Filled, Including Refills

Rank: 3 out of 79

$374K Total Retail Price of All Prescriptions

Rank: 6 out of 79

399 Patients Receiving at Least One Drug in Part D
94%Patients 65 Years and Older
0% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Puerto Rico
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

3% of this provider’s 10,060 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

28% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$36 was the average price of a prescription from this provider, compared to $52 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Puerto Rico
SIMVASTATIN 797 766 1 2
LOSARTAN POTASSIUM 591 575 2 1
AMLODIPINE BESYLATE 511 506 3 3
LOSARTAN-HYDROCHLOROTHIAZIDE 425 419 4 12
ENALAPRIL MALEATE 422 401 5 5
OMEPRAZOLE 374 363 6 11
LEVOTHYROXINE SODIUM 330 327 7 15
SYNTHROID 292 287 8 13
ATENOLOL 274 270 9 25
ZETIA 256 233 10 43
FUROSEMIDE 225 225 11 4
METOPROLOL SUCCINATE 215 211 12 21
GLYBURIDE-METFORMIN HCL 213 213 R 13 60
GABAPENTIN 189 182 14 6
COUMADIN 154 142 15 82
HYDROCHLOROTHIAZIDE 152 152 16 20
RANITIDINE HCL 143 130 17 10
DIGOXIN 137 137 18 86
ALENDRONATE SODIUM 136 127 19 51
CARVEDILOL 133 133 20 9
METFORMIN HCL 130 125 21 16
TAMSULOSIN HCL 130 130 21 34
CLOPIDOGREL 125 124 23 44
VYTORIN 121 121 24 74
ATORVASTATIN CALCIUM 117 117 25 19
DONEPEZIL HCL 110 110 26 93
PLAVIX 106 102 27 45
FAMOTIDINE 104 103 28 47
RAMIPRIL 89 89 29 28
LEVOXYL 88 80 30 101
LISINOPRIL 81 69 31 17
FLUOXETINE HCL 78 66 32 77
LANSOPRAZOLE 77 77 33 80
NAMENDA 73 73 34 110
WARFARIN SODIUM 71 71 35 83
FINASTERIDE 69 69 36 116
ISOSORBIDE MONONITRATE ER 65 64 37 23
ALLOPURINOL 64 64 38 18
METOPROLOL TARTRATE 62 62 39 22
EVISTA 61 54 40 88
CLONIDINE HCL 60 60 41 32
VERAPAMIL ER 58 58 42 56
SINGULAIR 57 51 43 128
GLYBURIDE MICRONIZED 56 56 R 44 132
PRAVASTATIN SODIUM 55 48 45 31
METFORMIN HCL ER 54 47 46 134
KLOR-CON 8 52 52 47 137
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.